Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Endocrine 2Lymphoid 1CNS 1

Conditions

Neuroendocrine Tumors 394Multiple Endocrine Neoplasia Type 1 156Carcinoma, Neuroendocrine 123Thyroid Cancer, Papillary 118Pituitary Neoplasms 116Thyroid Neoplasms 100Pheochromocytoma 91Neoplasms 79Carcinoid Tumor 76Thyroid Carcinoma, Anaplastic 73Adrenocortical Carcinoma 73Paraganglioma 65Neoplasm Metastasis 56Adenocarcinoma, Follicular 53Carcinoma, Non-Small-Cell Lung 51Carcinoma, Medullary 50Insulinoma 49Pancreatic Neoplasms 47Adenoma, Islet Cell 47Colorectal Neoplasms 44Breast Neoplasms 44Small Cell Lung Carcinoma 42Sarcoma 42Gastro-enteropancreatic neuroendocrine tumor 42Carcinoma, Renal Cell 41Somatostatinoma 38Head and Neck Neoplasms 38Melanoma 37Lung Neoplasms 37Adrenal Gland Neoplasms 34

Interventions

candesartan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Essential Hypertension × Endocrine × Clear all
NCT01022515 2026-02-06

PHEO

University Hospital, Rouen

Phase NA Completed
60 enrolled
CNSEndocrine

Essential Hypertension, Hypertension, Paraganglioma, Pheochromocytoma

NCT01629225 2014-11-18

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Third Military Medical University

Phase 4 Unknown
500 enrolled
Endocrine

Essential Hypertension, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡